Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 31, 2006. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares, executed under authority granted by shareholders at the Annual General Meeting on May 17, 2006.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 275,000 ordinary shares of 25 pence each.
- Purchase Price: 1,488.66 pence per share.
- Transaction Date: August 31, 2006.
- Treasury Holdings Post-Transaction: 191,616,678 shares.
- Shares in Issue (Excluding Treasury): 5,793,983,068 shares.
Material Changes
The material change reported is the reduction of outstanding shares through a buyback program. The company increased its treasury stock holdings by 275,000 shares. No other material changes to operations or financial position are disclosed in this specific filing.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase or subscribe for securities in any jurisdiction.
Key Facts for Investor Verification
- Verify the total cost of the repurchase (275,000 shares at 1,488.66 pence) against the company's cash position in broader financial reports.
- Confirm the updated total share count and treasury holdings in subsequent filings.
- Note that this filing is a notification of a specific transaction and does not replace quarterly or annual financial results.